Statement of Changes in Beneficial Ownership (4)
03 July 2021 - 7:09AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Schneiderman Daniel H |
2. Issuer Name and Ticker or Trading Symbol
AzurRx BioPharma, Inc.
[
AZRX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CHIEF FINANCIAL OFFICER |
(Last)
(First)
(Middle)
C/O AZURRX BIOPHARMA, INC., 777 YAMATO ROAD, SUITE 502 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/30/2021 |
(Street)
BOCA RATON, FL 33431
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock option (right to buy) | $0.85 | 6/30/2021 | | J (1) | | | 35006 | (2) | 7/15/2030 | Common Stock, par value $0.0001 per share | 35006 | $0 | 0 (2) | D | |
Stock option (right to buy) | $0.85 | 6/30/2021 | | A (1) | | 35006 | | (3) | 6/30/2031 | Common Stock, par value $0.0001 per share | 35006 | $0 | 35006 | D | |
Stock option (right to buy) | $0.85 | 6/30/2021 | | J (1) | | | 250000 | (4) | 7/15/2030 | Common Stock, par value $0.0001 per share | 250000 | $0 | 0 (4) | D | |
Stock option (right to buy) | $0.85 | 6/30/2021 | | A (1) | | 250000 | | (5) | 6/30/2031 | Common Stock, par value $0.0001 per share | 250000 | $0 | 250000 | D | |
Explanation of Responses: |
(1) | On June 30, 2021, the board of directors of AzurRx BioPharma, Inc. (the "Company") rescinded and cancelled stock option awards previously made to Mr. Schneiderman on July 16, 2020 covering an aggregate of 285,006 shares under the Company's Amended and Restated 2014 Omnibus Equity Incentive Plan and granted new stock options under the Company's 2020 Omnibus Equity Incentive Plan, as amended and restated, on substantially similar terms to the rescinded stock options. |
(2) | The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on February 3, 2020, conditioned on Mr. Schneiderman's continued employment by the Company on the applicable vesting date. |
(3) | The stock option vests (i) with respect to 17,502 shares immediately and (ii) with respect to 17,504 shares over a term of 19 months in 19 equal monthly installments, conditioned on Mr. Schneiderman's continued employment by the Company on the applicable vesting date. |
(4) | The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on August 16, 2020, conditioned on Mr. Schneiderman's continued employment by the Company on the applicable vesting date. |
(5) | The stock option vests (i) with respect to 79,860 shares immediately and (ii) with respect to 170,140 shares over a term of 2 years and 1 month in 25 equal monthly installments, conditioned on Mr. Schneiderman's continued employment by the Company on the applicable vesting date. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Schneiderman Daniel H C/O AZURRX BIOPHARMA, INC. 777 YAMATO ROAD, SUITE 502 BOCA RATON, FL 33431 |
|
| CHIEF FINANCIAL OFFICER |
|
Signatures
|
/s/ Daniel H. Schneiderman | | 7/2/2021 |
**Signature of Reporting Person | Date |
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Apr 2024 to May 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about AzurRx BioPharma Inc (NASDAQ): 0 recent articles
More Azurrx Biopharma, Inc. News Articles